Journal article
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1
Journal of acquired immune deficiency syndromes (1999), Vol.38(3), pp.283-288
2005
DOI: 10.1097/01.qai.0000149791.37205.b1
PMID: 15735445
Abstract
Objective: To determine nevirapine (NVP) plasma levels during the postpartum period after a single intrapartum NVP dose for the prevention of mother-to-child transmission.
Methods: Plasma samples at delivery and during days 8 to 45 postpartum were obtained from HIV-infected Thai women who received an intrapartum NVP dose in the Perinatal HIV Prevention Clinical Trial-2 (PHPT-2) for the prevention of perinatal HIV transmission. These data were combined with NVP concentration data from 2 phase 1 studies of NVP for a population analysis.
Results: The median NVP level fell to 68 ng/mL (range: <50-228, n = 43) 8 to 14 days after dosing and to 51 ng/mL (range: <50-166, n = 25) between 15 and 21 days. During the second and third weeks postpartum, NVP levels were below the limit of quantitation in 23% and 44% of samples, respectively. Between 21 and 45 days, no sample had a quantifiable NVP concentration. A simulation derived from the population analysis predicts that NVP concentration falls to less than 10 ng/mL in 5% of women by 11 days, in 50% of women by 17.5 days, and in 95% of women by 28 days.
Conclusions: Significant NVP concentrations remained for up to 20 days in these Thai women. To ensure that coverage is maintained until NVP concentrations fall to nonsuppressive levels, 1 month of additional antiretroviral treatment after delivery should be considered to prevent the emergence of resistant viruses.
Details
- Title: Subtitle
- Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1
- Creators
- Tim R CRESSEY - Harvard School of Public Health, Boston, MA, United StatesGonzague JOURDAIN - Harvard School of Public Health, Boston, MA, United StatesMarc J LALLEMANT - Institut de Recherche pour le Developpement, 054 Perinatal HIV Prevention Trial, Chiang Mai, ThailandSuparat KUNKEAW - Institut de Recherche pour le Developpement, 054 Perinatal HIV Prevention Trial, Chiang Mai, ThailandJ. Brooks JACKSON - Johns Hopkins School of Medicine, Baltimore, MD, United StatesPhilippa MUSOKE - Institut de Recherche pour le Developpement, 054 Perinatal HIV Prevention Trial, Chiang Mai, ThailandEdmund CAPPARELLI - University of California Pediatric Pharmacology Research Unit, San Diego, CA, United StatesMark MIROCHNICK - Institut de Recherche pour le Developpement, 054 Perinatal HIV Prevention Trial, Chiang Mai, Thailand
- Resource Type
- Journal article
- Publication Details
- Journal of acquired immune deficiency syndromes (1999), Vol.38(3), pp.283-288
- Publisher
- Lippincott Williams & Wilkins; Hagerstown, MD
- DOI
- 10.1097/01.qai.0000149791.37205.b1
- PMID
- 15735445
- ISSN
- 1525-4135
- eISSN
- 1944-7884
- Language
- English
- Date published
- 2005
- Academic Unit
- Pathology; VPMA - Administration
- Record Identifier
- 9984047985302771
Metrics
23 Record Views